Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trialAlexandre Mebazaa, Gad Cotter, Beth A. Davison et al.|The Lancet|2022Cited by 1k
Signature of Circulating microRNAs in Patients with Acute Heart FailureEkaterina S. Ovchinnikova, Eugène Berezikov, Daniela Schmitter et al.|European Journal of Heart Failure|2015Cited by 203
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failureGuillermo Torre‐Amione, Isaac Kobrin, James B. Young et al.|Journal of the American College of Cardiology|2003Cited by 119
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection FractionMatteo Pagnesi, Beth A. Davison, Marco Metra et al.|Journal of the American College of Cardiology|2023Cited by 72
The Hemodynamic and Neurohormonal Effects of Low Doses of Tezosentan (An Endothelin A/B Receptor Antagonist) in Patients with Acute Heart FailureGad Cotter, Guillermo Torre‐Amione, Karl Stangl et al.|European Journal of Heart Failure|2004Cited by 58